Financial institution of The us analysts upgraded BioNTech SE stock to acquire from maintain on Thursday, citing enjoyment about its mRNA engineering and the outlook for a merged flu/COVID vaccine and oncology vaccines that are at present in different phases of improvement.
Analysts led by Tazeen Ahmad reiterated their $239 value goal on the stock BNTX, which is 28.5% above its latest cost, and claimed the German company’s about 16 billion euros in cash is a beneficial.
“The…